Fusion proteins for the treatment of disease

JP2023548311A5Inactive Publication Date: 2024-11-07BRISTOL MYERS SQUIBB CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526282
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-10
Filing Date
2021-10-29
Publication Date
2024-11-07
Estimated Expiration
Not applicable · inactive patent
Patent Text Reader

Abstract

Disclosed herein are methods for treating a disease or disorder in a subject in need thereof, comprising administering to the subject one or more doses of an interleukin-2 (IL2) fusion protein, wherein the dose is between about 0.1 mg and about 9 mg. Also disclosed herein are methods for treating a disease or disorder in a subject in need thereof, comprising administering to the subject a dose of an IL2 fusion protein, wherein the dose is greater than about 9 mg. The IL2 fusion protein used in the methods disclosed herein comprises (a) a first polypeptide comprising an IL2 polypeptide; and (b) a second polypeptide comprising the extracellular domain of an IL2 receptor alpha (IL2R) polypeptide. In some embodiments, the disease or disorder is an immune-mediated disease such as systemic lupus erythematosus. In some embodiments, the method further comprises administering to the subject a corticosteroid.
Need to check novelty before this filing date? Find Prior Art

Claims

1. An interleukin-2 (IL2) fusion protein for use in treating a disease or disorder in a subject in need thereof, wherein a dose of the IL2 fusion protein is administered to the subject, and the fusion protein comprises: a first polypeptide comprising an IL2 polypeptide; and A second polypeptide comprising the extracellular domain of an interleukin-2 receptor alpha (IL2Rα) polypeptide. Including; (i) the extracellular domain of the IL2Rα polypeptide has at least one less glycosylation site compared to the extracellular domain of native IL2Rα (SEQ ID NO:1); and / or (ii) the IL2 polypeptide has at least one less glycosylation site compared to native IL2 (SEQ ID NO:2); and The dosage is from about 0.3 mg to about 9 mg. Fusion proteins.

2. 2. The fusion protein for use according to claim 1, wherein the fusion protein is administered to a subject via intravenous, subcutaneous, topical, epidermal, mucosal, intranasal, oral, intravaginal, rectal, sublingual, intraperitoneal, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, transtracheal, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural or intrasternal routes.

3. The fusion protein for use according to claim 2, wherein the fusion protein is administered to a subject via the intravenous route.

4. The fusion protein for use according to claim 2, wherein the fusion protein is administered to a subject via the subcutaneous route.

5. The fusion protein for use according to any one of claims 1 to 4, wherein the dose is about 1 mg, about 3 mg, about 6 mg, or about 8 mg.

6. 6. The fusion protein for use according to any one of claims 1 to 5, wherein two or more of the doses are administered with a dosing interval between the two doses, the dosing interval being at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least about 1 month, at least about 5 weeks, at least about 6 weeks, at least about 7 weeks, at least about 8 weeks, at least about 2 months, at least about 9 weeks, at least about 10 weeks, at least about 11 weeks, at least about 12 weeks, or at least about 3 months.

7. The fusion protein for use according to claim 6, wherein the dosing interval is about 3 weeks.

8. The fusion protein for use according to claim 6 or 7, wherein the dosing intervals are the same or different throughout the dose.

9. 9. The fusion protein for use according to any one of claims 6 to 8, wherein at least one of the two or more doses is administered intravenously and at least one of the two or more doses is administered subcutaneously.

10. 10. The fusion protein for use according to any one of claims 1 to 9, wherein the disease or disorder comprises an infectious disease or an immune-mediated disease.

11. Immune-mediated diseases include type 1 diabetes; multiple sclerosis; rheumatoid arthritis; celiac disease; systemic lupus erythematosus; lupus nephritis; cutaneous lupus; juvenile idiopathic arthritis; Crohn's disease; ulcerative colitis; systemic sclerosis; graft-versus-host disease (GvHD); psoriasis; alopecia areata; HCV-induced vasculitis; Sjogren's syndrome; pemphigus; ankylosing spondylitis; Behcet's disease; Wegener's granulomatosis; Takayasu's disease ; Autoimmune hepatitis; sclerosing cholangitis; Gujeró-Sjögren's disease; 11. The fusion protein for use according to claim 10, selected from the group consisting of inflammatory bowel disease; immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome; and macrophage activation syndrome.

12. The fusion protein for use according to claim 10 or 11, wherein the subject is administered a corticosteroid.

13. The fusion protein for use as described in claim 12, wherein: (a) the corticosteroid is administered to the subject via topical, oral, intravenous, or intramuscular routes; (b) the corticosteroid is administered before, simultaneously with, or after each dose of the fusion protein; or (c) both (a) and (b).

14. A fusion protein for use as described in any one of claims 1 to 13, wherein: (a) the extracellular domain of the IL2Rα polypeptide has at least one less glycosylation site, at least two less glycosylation sites, at least three less glycosylation sites, at least four less glycosylation sites, at least five less glycosylation sites, at least six less glycosylation sites, at least seven less glycosylation sites, at least eight less glycosylation sites, or at least nine less glycosylation sites compared to the extracellular domain of native IL2Rα (SEQ ID NO: 1); (b) the IL2 polypeptide has at least one less glycosylation site compared to native IL2 (SEQ ID NO: 2); or (c) both (a) and (b).

15. A fusion protein for use according to any one of claims 1 to 14, wherein: (a) the first polypeptide comprises an amino acid sequence that is at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO:2; (b) the second polypeptide comprises an amino acid sequence that is at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO:3; or (c) both (a) and (b).